Advertisement

Search Results

Advertisement



Your search for Toni K. Choueiri, MD matches 69 pages

Showing 1 - 50


kidney cancer
immunotherapy

KEYNOTE-564 Trial: Adjuvant Pembrolizumab Improves Disease-Free Survival in High-Risk Renal Cell Carcinoma

As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and colleagues, an interim analysis of the phase III KEYNOTE-564 trial has showed improved disease-free survival with adjuvant pembrolizumab vs placebo after nephrectomy in high-risk...

kidney cancer

Is Cabozantinib Active in Treating Brain Metastases From Renal Cell Carcinoma?

In a retrospective cohort study reported in JAMA Oncology, Hirsch et al found that cabozantinib showed substantial activity in treating brain metastases in patients with renal cell carcinoma. As stated by the investigators, “Patients with brain metastases from renal cell carcinoma have been...

kidney cancer
immunotherapy

Toni K. Choueiri, MD, on Renal Cell Carcinoma: Quality-of-Life Data From KEYNOTE-564 on Pembrolizumab vs Placebo

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses patient-reported outcomes for quality of life in the KEYNOTE-564 study, which previously met its primary endpoint of disease-free survival with adjuvant pembrolizumab vs placebo following surgery for renal cell carcinoma (Abstract...

kidney cancer

KEYNOTE-564: Adjuvant Pembrolizumab Extends Disease-Free Survival in High-Risk Renal Cell Carcinoma

Adjuvant pembrolizumab following surgery significantly improved disease-free survival compared with placebo among patients with high-risk clear cell renal cell carcinoma (RCC), according to the international phase III KEYNOTE-564 study presented at the Plenary session during the 2021 ASCO Annual...

Introducing the ASCO Plenary Series: Because Today’s Science Is Needed Quickly for Tomorrow’s Practice

Research advances are being made faster than ever before, yet it often takes several months before study results can be presented at an upcoming conference. Faster dissemination of practice-changing science is needed to better help clinicians deliver the most up-to-date care and treatments to...

kidney cancer
immunotherapy

Adjuvant Pembrolizumab May Improve Disease-Free Survival in Patients With High-Risk Renal Cell Carcinoma

As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, and colleagues, an interim analysis of the phase III KEYNOTE-564 trial showed improved disease-free survival with adjuvant pembrolizumab vs placebo after nephrectomy in high-risk patients with clear cell renal cell...

kidney cancer
immunotherapy

KEYNOTE-564: Adjuvant Pembrolizumab Extends Disease-Free Survival in High-Risk Renal Cell Carcinoma

Adjuvant pembrolizumab following surgery significantly improved disease-free survival compared with placebo among patients with high-risk clear cell renal cell carcinoma (RCC), according to the international phase III KEYNOTE-564 study presented at the Plenary session during the 2021 ASCO Annual...

kidney cancer
immunotherapy

Adjuvant Pembrolizumab Extends Disease-Free Survival in High-Risk Renal Cell Carcinoma

Immunotherapy following surgery significantly improved disease-free survival compared to placebo among patients with high-risk clear cell renal cell carcinoma (RCC), according to results from the international phase III KEYNOTE-564 study presented at the 2021 ASCO Annual Meeting by Toni K....

kidney cancer
immunotherapy

Toni K. Choueiri, MD, on Renal Cell Carcinoma: Pembrolizumab vs Placebo in Adjuvant Treatment

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses phase III results from KEYNOTE-564, which evaluated the safety and efficacy of pembrolizumab in the adjuvant treatment of patients with renal cell carcinoma who have undergone nephrectomy for intermediate-high or high-risk disease or...

kidney cancer
immunotherapy

First-Line Nivolumab Plus Cabozantinib Improves Progression-Free and Overall Survival vs Sunitinib in Advanced Renal Cell Carcinoma

As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, of Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, and colleagues, the phase III CheckMate 9ER trial has shown that the combination of nivolumab and cabozantinib improved progression-free survival and...

kidney cancer

Belzutifan Shows Activity in Advanced Renal Cell Carcinoma, Both as a Single Agent and in Combination Therapy

Separate studies presented at the 2021 Genitourinary Cancers Symposium provide supportive evidence for belzutifan (formerly MK-6482) as an active treatment for metastatic clear cell renal cell carcinoma (RCC). One study showed single-agent activity for this novel approach in an early-phase trial,...

kidney cancer
immunotherapy

CheckMate 9ER: First-Line Nivolumab Plus Cabozantinib vs Sunitinib for Advanced Renal Cell Carcinoma

As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, and colleagues, the phase III CheckMate 9ER trial has shown that the combination of nivolumab and cabozantinib improved progression-free survival and overall survival vs sunitinib in first-line treatment of patients with...

kidney cancer
immunotherapy

Immunotherapy for Advanced Kidney Cancer: Effect of Body Mass Index

In a study reported in a research letter in JAMA Oncology, Lalani et al found that higher body mass index (BMI) was associated with better overall survival among patients with metastatic renal cell carcinoma receiving anti­–PD-1/PD-L1–based immune checkpoint inhibitor treatment. No association of...

covid-19

Toni K. Choueiri, MD, on the Effects of Cancer Treatments on Patients Infected With COVID-19

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses the challenges of delivering optimal cancer treatments in the face of the coronavirus pandemic. Focusing on systemic therapies, he reviews prognostic factors in people with cancer and COVID-19 (Symposium 9).

kidney cancer

Toni K. Choueiri, MD, on Clear Cell RCC: Treatment With Belzutifan Plus Cabozantinib

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discuses a preliminary phase II analysis of the HIF-2a inhibitor belzutifan in combination with cabozantinib, which showed antitumor activity in previously treated patients with metastatic clear cell renal cell carcinoma (Abstract 272).

kidney cancer
immunotherapy

Toni K. Choueiri, MD, on RCC: Treatment With Lenvatinib Plus Pembrolizumab or Everolimus vs Sunitinib

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses phase III results of the CLEAR study, which showed that for first-line treatment of advanced renal cell carcinoma, lenvatinib plus pembrolizumab improved outcomes vs sunitinib. Lenvatinib plus everolimus also improved progression-free ...

kidney cancer
immunotherapy

Response-Based Management of Nivolumab and Ipilimumab Therapy in Metastatic Renal Cell Carcinoma

In the phase II OMNIVORE study reported in the Journal of Clinical Oncology, Rana R. McKay, MD, and colleagues did not find evidence supporting a strategy of discontinuing nivolumab monotherapy in responders and adding ipilimumab in nivolumab nonresponders among patients with metastatic renal cell...

kidney cancer
immunotherapy

First-Line Nivolumab Plus Cabozantinib Improves Outcomes vs Sunitinib in Advanced Renal Cell Carcinoma

The combination of nivolumab plus cabozantinib was found to be superior to the former standard, sunitinib, in the first-line treatment of advanced or metastatic renal cell carcinoma, according to the results of the phase III CheckMate 9ER trial reported at the European Society for Medical Oncology...

kidney cancer
immunotherapy

Toni K. Choueiri, MD, on RCC: Nivolumab Plus Cabozantinib vs Sunitinib in First-Line Treatment

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses the first results from the phase III CheckMate 9ER trial, which suggested the combination of nivolumab and cabozantinib is safe. It showed activity in progression-free and overall survival, as well as in overall response rates and may ...

kidney cancer
immunotherapy

CheckMate 9ER Trial Shows Benefit of Novel Doublet for Advanced Kidney Cancer

The combination of nivolumab plus cabozantinib was superior to the former standard, sunitinib, as first-line treatment for advanced/metastatic renal cell carcinoma, according to results of the phase III CheckMate 9ER trial reported by Toni K. Choueiri, MD, and colleagues at the ESMO Virtual...

Expert Point of View: Toni K. Choueiri, MD

At the Genitourinary Highlights session of the ASCO20 Virtual Scientific Program, Toni K. Choueiri, MD, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, Boston, put the findings from KEYNOTE-426 into perspective. “This is an important update. The initial...

covid-19
solid tumors
hematologic malignancies

In Case You Missed It: Quick Takes on Novel Therapies for Solid and Hematologic Malignancies

Because of the COVID-19 pandemic, oncology providers from around the world had to forgo their annual trip to McCormick Place—but the show did go on. We all realized important research can still be presented, clinicians and fellow researchers will still listen, and ASCO presentations will still...

bladder cancer
immunotherapy

Expert Point of View: Daniel Y. Heng, MD, MPH, and Toni K. Choueiri, MD

Study discussant Daniel Y. Heng, MD, MPH, a medical oncologist at Tom Baker Cancer Centre, University of Calgary, Canada, called the negative trial results important. IMvigor010 randomly assigned patients with high-risk muscle-invasive urothelial carcinoma to adjuvant atezolizumab or observation...

Expert Point of View: Toni K. Choueiri, MD

At the Genitourinary Highlights session of the ASCO20 Virtual Scientific Program, Toni K. Choueiri, MD, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, Boston, put these findings into perspective. “This is an important update. The initial publication was with ...

kidney cancer
immunotherapy

Immune Checkpoint Inhibitor Rechallenge in Metastatic Renal Cell Carcinoma

In a study presented at the ASCO20 Virtual Scientific Program (Abstract 5077) and published as a brief report in JAMA Oncology, Ravi et al found that rechallenge with immune checkpoint inhibitor therapy was capable of producing responses in patients with metastatic renal cell carcinoma, including...

kidney cancer
immunotherapy

Toni K. Choueiri, MD, on COSMIC-313: Cabozantinib in Combination With Nivolumab/Ipilimumab in RCC

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, describes a currently recruiting phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab vs nivolumab/ipilimumab for patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk ...

kidney cancer

Toni K. Choueiri, MD, on an HIF2A Inhibitor for Advanced Clear Cell RCC

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses findings from a phase I/II trial that found MK-6482 was well tolerated and demonstrated activity in heavily pretreated patients with clear cell renal cell carcinoma (Abstract 611).

kidney cancer
immunotherapy

Atezolizumab/Bevacizumab in Metastatic Renal Cell Carcinoma With Variant Histology or Sarcomatoid Features

In a phase II trial reported in the Journal of Clinical Oncology, Toni K. Choueiri, MD, and colleagues found that the combination of atezolizumab and bevacizumab was active in metastatic renal cell carcinoma with variant histology and clear cell renal cell carcinoma with ≥ 20% sarcomatoid...

kidney cancer
immunotherapy

Ziad Bakouny, MD, and Toni K. Choueiri, MD, on Renal Cell Carcinoma: Checkpoint Inhibitors and Genomic Characterization of Sarcomatoid/Rhabdoid Disease

Toni K. Choueiri, MD, and Ziad Bakouny, MD, both of Dana-Farber Cancer Institute, discuss a retrospective review of genomically profiled patients with sarcomatoid/rhabdoid renal cell cancer who were found to have better outcomes with immune checkpoint inhibitors and to harbor mutations associated...

solid tumors
immunotherapy

Sarah Abou Alaiwi, MD, and Toni K. Choueiri, MD, on Checkpoint Inhibitors: Overall Survival and Polybromo-Associated Mutations

Toni K. Choueiri, MD, and Sarah Abou Alaiwi, MD, both of Dana-Farber Cancer Institute, discuss the association of polybromo-associated BAF-type mutations with overall survival in patients with different solid tumors treated with checkpoint inhibitors (Abstract 103).

kidney cancer

Early Tumor Shrinkage and Outcomes Following Cabozantinib or Everolimus

IN A RETROSPECTIVE analysis of median  overall survival from the phase III ­METEOR  trial,1 ­Ignacio Duran, MD, PhD, and colleagues sought to determine whether early tumor shrinkage following therapy with cabozantinib or everolimus could be an early indicator of prognosis for patients with...

kidney cancer

Evaluating Outcomes of Cabozantinib vs Everolimus in Advanced Renal Cell Carcinoma

IN A RETROSPECTIVE analysis of median overall survival from the phase III METEOR trial,1 Ignacio Duran, MD, PhD, and colleagues sought to determine whether early tumor shrinkage following therapy with cabozantinib or everolimus could be an early indicator of prognosis for patients with metastatic...

kidney cancer
immunotherapy

JAVELIN Renal 101: Avelumab Plus Axitinib vs Sunitinib in the First-Line Treatment of Advanced Kidney Cancer

THE PROGRAMMED cell death-ligand 1 (PD-L1) inhibitor, avelumab, was combined with the multitargeted vascular growth endothelial factor (VEGF) agent, axitinib, and compared to monotherapy with sunitinib in the first-line treatment of patients with metastatic renal cell carcinoma. Toni K. Choueiri,...

kidney cancer
immunotherapy

Toni K. Choueiri, MD, and Ziad Bakouny, MD, on Renal Cell Carcinoma: Next-Generation Immuno-oncology Therapies

Toni K. Choueiri, MD, and Ziad Bakouny, MD, both of Dana-Farber Cancer Institute, talk about novel cytokines, checkpoint inhibitors, and vaccines in the treatment pipeline for renal cell carcinoma.

kidney cancer
immunotherapy

Toni K. Choueiri, MD, on Renal Cell Carcinoma: Trial Results on Avelumab Plus Axitinib vs Sunitinib

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses a subgroup analysis from the JAVELIN Renal 101 study on outcomes for avelumab plus axitinib vs sunitinib in advanced renal cell carcinoma (Abstract 544).

kidney cancer
immunotherapy

2019 GU Cancers Symposium: JAVELIN Renal 101: Avelumab Plus Axitinib vs Sunitinib for Advanced Kidney Cancer

A combination of two drugs could become a new standard first-line treatment for patients with metastatic kidney cancer, according to results from the JAVELIN Renal 101 trial presented at the 2019 Genitourinary Cancers Symposium (Abstract 544) and simultaneously published in The New England...

kidney cancer
immunotherapy

Toni K. Choueiri, MD, and Elizabeth R. Plimack, MD, on RCC: Perspectives on KEYNOTE-427 and IMmotion151

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, offer their analysis of two key studies presented in renal cell cancer.

bladder cancer

Toni K. Choueiri, MD, and Jonathan E. Rosenberg, MD: Bladder Cancer Roundup

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discuss their perspectives on the top abstracts in bladder cancer presented at the 2018 ASCO Annual Meeting (Abstracts 4507, 4506, 4503, 4504).

kidney cancer
immunotherapy

Toni K. Choueiri, MD, and Lauren C. Harshman, MD on RCC: Results From the PROSPER Trial

Toni K. Choueiri, MD, and Lauren C. Harshman, MD, both of Dana-Farber Cancer Institute, discuss phase III study findings on perioperative nivolumab vs observation in patients with localized renal cell carcinoma undergoing nephrectomy (Abstract TPS4597).

kidney cancer
immunotherapy

Laurence Albiges, MD, PhD, and Toni K. Choueiri, MD, on RCC: Novel Combinations for Advanced Disease

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of Gustave Roussy, discuss two treatment studies: one testing pegilodecakin with nivolumab or pembrolizumab and the other evaluating an oral CXCR4 inhibitor in combination with axitinib (Abstracts 4509 & 4510).

kidney cancer

Laurence Albiges, MD, PhD, and Toni K. Choueiri, MD, on Metastatic RCC: Perspectives on the Carmena Trial

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of Gustave Roussy, discuss the implications of this study’s potentially practice-changing finding that nephrectomy is no longer the standard of care for patients with metastatic renal cell carcinoma (Abstract...

solid tumors
kidney cancer

Combined Immune Checkpoint and VEGF Inhibition as First-Line Therapy in Advanced Clear Cell Kidney Cancer

In a dose-finding, dose-expansion phase Ib trial (JAVELIN Renal 100) reported in The Lancet Oncology, Toni K. Choueiri, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, and colleagues determined the maximum tolerated dose of the immune checkpoint inhibitor avelumab (Bavencio)...

kidney cancer
immunotherapy

Activity of Combined Immune Checkpoint and VEGF Inhibition as First-Line Therapy in Advanced Clear Cell RCC

In the dose-finding, dose-expansion phase Ib JAVELIN Renal 100 trial reported in The Lancet Oncology, Choueiri et al identified the maximum tolerated dose of the immune checkpoint inhibitor avelumab (Bavencio) in combination with the vascular endothelial growth factor inhibitor axitinib...

bladder cancer
immunotherapy

Avelumab in Advanced Urothelial Carcinoma: Further Study Needed to Clarify its Role

AS REVIEWED in this issue of The ASCO Post, Patel and colleagues have presented data from the phase I JAVELIN study evaluating avelumab (Bavencio) in platinum-refractory patients with advanced urothelial carcinoma.1 The drug is active with durable responses when compared with historical...

kidney cancer

Toni K. Choueiri, MD, on RCC: Results From the CABOSUN Trial

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses updated overall survival results on cabozantinib vs sunitinib as initial targeted treatment for patients with metastatic renal cell carcinoma (Abstract LBA38).

kidney cancer

MET Inhibitor Savolitinib in Advanced Papillary Renal Cell Cancer

In a biomarker-based phase II trial reported in the Journal of Clinical Oncology, Choueiri et al found that the MET tyrosine kinase inhibitor savolitinib was active in MET-driven advanced papillary renal cell cancer. Study Details In the trial, 109 patients with locally advanced or metastatic...

kidney cancer

Toni K. Choueiri, MD, and Sumanta K. Pal, MD, on Top Kidney Cancer Abstracts: Expert Perspectives

Sumanta K. Pal, MD, of City of Hope, and Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, exchange views on the key papers in renal cell carcinoma presented at ASCO’s 2017 nonprostate GU oral abstract session. (Abstracts 4504, 4505, 4506, 4507, 4508)

kidney cancer

Toni K. Choueiri, MD, on Untreated RCC: Phase II Trial Results

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses study findings on atezolizumab with or without bevacizumab vs sunitinib in patients with untreated metastatic renal cell carcinoma. (Abstract 431)

kidney cancer

Toni K. Choueiri, MD, on Papillary RCC: Phase II Trial Results

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses a single-arm biomarker-based study of savolitinib in patients with advanced papillary renal cell cancer. (Abstract 436)

bladder cancer

Toni K. Choueiri, MD, on Urothelial Cancer: Trial Results From Borealis-2

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses study findings on apatorsen plus docetaxel vs docetaxel alone in platinum-resistant metastatic urothelial cancer. (Abstract 289)

Advertisement

Advertisement



Advertisement